Courtney D DiNardo Selected Research

enasidenib

3/2024	Differentiation syndrome associated with treatment with IDH2 inhibitor enasidenib - pooled analysis from clinical trials.
12/2023	Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial.
1/2023	Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome.
1/2022	Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy.
11/2021	Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial.
1/2021	Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study.
4/2020	Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial.
1/2020	How I treat acute myeloid leukemia in the era of new drugs.
12/2019	Which novel agents hold the greatest promise in AML?
11/2019	Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Courtney D DiNardo Research Topics

Disease

131	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 05/2024 - 01/2008
38	Neoplasms (Cancer) 03/2024 - 06/2013
28	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 04/2024 - 01/2015
13	Hematologic Neoplasms (Hematological Malignancy) 02/2024 - 01/2016
11	Thrombocytopenia (Thrombopenia) 02/2024 - 10/2019
11	Leukemia 01/2023 - 03/2012
8	Philadelphia Chromosome 06/2023 - 12/2018
7	Neutropenia 02/2024 - 01/2020
7	Infections 11/2023 - 01/2018
7	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 10/2023 - 01/2019
6	Acute Promyelocytic Leukemia 02/2024 - 01/2008
6	Exanthema (Rash) 11/2023 - 11/2017
6	B-Cell Lymphoma (Lymphoma, B Cell) 01/2022 - 01/2018
5	Anemia 01/2023 - 01/2019
5	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2023 - 01/2019
5	Febrile Neutropenia 12/2022 - 01/2020
4	Disease Progression 05/2024 - 01/2021
4	Nausea 11/2023 - 09/2018
4	Hemorrhage 01/2023 - 12/2018
4	Pneumonia (Pneumonitis) 12/2022 - 11/2021
4	Hyperbilirubinemia 01/2022 - 10/2017
3	Chronic Myelomonocytic Leukemia (Leukemia, Chronic Myelomonocytic) 03/2024 - 01/2021
3	Chromosome Aberrations (Chromosome Abnormalities) 01/2023 - 01/2018
3	Primary Myelofibrosis (Myelosclerosis) 01/2021 - 10/2018
3	Lymphoma (Lymphomas) 01/2020 - 10/2016
2	Residual Neoplasm 02/2024 - 01/2018
2	Invasive Fungal Infections 02/2024 - 10/2022
2	Tumor Lysis Syndrome 03/2023 - 01/2019
2	Myocardial Infarction 01/2023 - 12/2018
2	Pancreatitis 01/2023 - 12/2018
2	Hypertension (High Blood Pressure) 01/2023 - 12/2018
2	Cytopenia 11/2022 - 01/2021
2	Pathologic Complete Response 07/2020 - 12/2018
2	Sepsis (Septicemia) 07/2020 - 01/2018
2	Graft vs Host Disease (Graft-Versus-Host Disease) 01/2020 - 09/2019
2	B-Cell Leukemia (Leukemia, B Cell) 01/2020 - 10/2016
2	Fibrosis (Cirrhosis) 01/2019 - 10/2018
1	Second Primary Neoplasms (Neoplasms, Second) 03/2024
1	Acute Kidney Injury (Acute Renal Failure) 12/2023
1	Fever (Fevers) 11/2023

Drug/Important Bio-Agent (IBA)

59	venetoclaxIBA 04/2024 - 10/2016
24	Azacitidine (5 Azacytidine)FDA Link 02/2024 - 01/2015
19	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 01/2024 - 06/2013
15	Decitabine FDA Link 04/2024 - 01/2018
15	Cytarabine (Cytosar-U)FDA LinkGeneric 11/2023 - 08/2013
14	enasidenibIBA 03/2024 - 10/2017
13	ivosidenibIBA 02/2024 - 01/2016
8	Proteins (Proteins, Gene)FDA Link 01/2023 - 03/2012
7	Tyrosine Kinase InhibitorsIBA 01/2023 - 01/2019
5	BilirubinIBA 11/2023 - 09/2018
4	Cladribine FDA LinkGeneric 11/2023 - 01/2021
4	Idarubicin (4 Demethoxydaunorubicin)FDA LinkGeneric 11/2023 - 11/2017
4	Immune Checkpoint InhibitorsIBA 06/2023 - 10/2021
4	DNA (Deoxyribonucleic Acid)IBA 01/2023 - 01/2016
4	NivolumabIBA 01/2023 - 01/2019
4	MethyltransferasesIBA 01/2023 - 01/2021
4	Lenalidomide (CC 5013)FDA Link 10/2022 - 01/2015
3	Tretinoin (Retinoic Acid)FDA LinkGeneric 02/2024 - 01/2008
3	Arsenic Trioxide (Trisenox)FDA Link 02/2024 - 01/2019
3	Inotuzumab OzogamicinIBA 10/2023 - 01/2021
3	Lysine (L-Lysine)FDA Link 01/2023 - 01/2021
3	isocitric acid (isocitrate)IBA 01/2023 - 01/2019
3	Transaminases (Aminotransferases)IBA 01/2023 - 11/2017
3	ponatinibIBA 01/2023 - 12/2018
3	Biomarkers (Surrogate Marker)IBA 10/2022 - 01/2019
3	fms-Like Tyrosine Kinase 3IBA 01/2021 - 01/2019
3	Clofarabine (Clolar)FDA Link 01/2021 - 11/2017
3	Vincristine (Oncovin)FDA LinkGeneric 01/2021 - 01/2017
3	ruxolitinibIBA 01/2020 - 10/2018
3	alpha-hydroxyglutarateIBA 01/2020 - 06/2013
2	Transcription Factors (Transcription Factor)IBA 05/2024 - 01/2021
2	posaconazole FDA Link 02/2024 - 02/2017
2	TriazolesIBA 02/2024 - 10/2022
2	blinatumomabIBA 06/2023 - 01/2021
2	NucleophosminIBA 01/2023 - 01/2021
2	EnzymesIBA 01/2023 - 01/2021
2	Programmed Cell Death 1 ReceptorIBA 01/2023 - 11/2021
2	AnthracyclinesIBA 05/2022 - 10/2020
2	Protein Isoforms (Isoforms)IBA 01/2022 - 12/2018
2	CreatinineIBA 01/2022 - 12/2018
2	Core Binding Factors (Core-Binding Factor)IBA 01/2021 - 01/2021
2	Hemoglobins (Hemoglobin)IBA 01/2021 - 12/2020
2	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2021 - 01/2017
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2021 - 01/2017
2	Vascular Endothelial Growth Factor Receptor-1 (fms-Like Tyrosine Kinase)IBA 01/2021 - 01/2021
2	gilteritinibIBA 01/2020 - 12/2019
2	midostaurinIBA 01/2020 - 12/2019
2	Prednisone (Sone)FDA LinkGeneric 12/2018 - 01/2017
2	fludarabineIBA 01/2018 - 11/2017
2	Purine NucleosidesIBA 01/2018 - 11/2017
1	Voriconazole (Vfend)FDA LinkGeneric 02/2024
1	RNA Splicing FactorsIBA 11/2023

Therapy/Procedure

68	Therapeutics 03/2024 - 06/2013
43	Drug Therapy (Chemotherapy) 05/2024 - 01/2008
7	Stem Cell Transplantation 01/2023 - 01/2018
4	Salvage Therapy 01/2021 - 01/2018
3	Induction Chemotherapy 01/2022 - 09/2019
3	Aftercare (After-Treatment) 01/2020 - 03/2012
2	Remission Induction 10/2022 - 10/2020
2	Radiotherapy 10/2022 - 01/2020